Allergy Therapeutics Presents Promising Data From Phase III Allergy Study
Posted on: Thursday, 15 May 2008, 06:00 CDT
Allergy Therapeutics has announced positive results from its Pollinex Quattro Grass Phase III study, G301, a controlled allergy vaccine study.
The double-blind, placebo-controlled G301 study has examined the safety and efficacy of Pollinex Quattro in the treatment of seasonal allergic rhino-conjunctivitis (SAR) caused by grass pollen. The study compares the symptom or medication score of patients given four injections of Pollinex Quattro to those patients receiving placebo. Before entry into the study, patients had suffered from SAR for an average of over 20 years and reported having moderate to severe symptoms.
Patients were randomly and equally allocated to receive Pollinex Quattro or placebo. In the intent to treat population (all patients in the study) there was a 13.3% improvement with Pollinex Quattro over placebo (p = 0.0038), as measured by a reduction of the combined symptom/medication score (the primary efficacy endpoint). In the prospectively defined patient population who fully recorded key outcomes, Pollinex Quattro showed a dramatic improvement of 26.9% over placebo (p = 0.0031) in the same efficacy endpoint.
The study met its primary efficacy endpoint and demonstrated that Pollinex Quattro has statistically significant clinical benefits over placebo. The company intends to use the results to support a marketing approval application in the EU with a submission planned for the first quarter of 2009.
Source: Datamonitor
Related Articles
- Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
- Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
- Genzyme's Myozyme Meets Co-Primary Efficacy Endpoints
- Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
- Medivation's Dimebon(TM) Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy
- Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
- Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study; Conference Call Begins at 1:00 P.M. Eastern Time Today
- Altus Pharmaceuticals Presents Results From ALTU-135 (TheraCLEC(TM)) Phase II Study in Cystic Fibrosis Patients With Pancreatic Insufficiency
- A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis*
- Nabi Biopharmaceuticals Announces Initiation of New StaphVAX(R) Immunogenicity Study in Orthopedic Surgery Patients
 |
 |
User Comments (0)
RSS Feeds